Premium
The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; The results of multicenter, prospective Polish adult leukemia group study
Author(s) -
Grosicki Sebastian,
Holowiecki Jerzy,
Giebel Sebastian,
KyrczKrzemien Slawomira,
Kuliczkowski Kazimierz,
Kielbinski Marek,
Skotnicki Aleksander B.,
PiatkowskaJakubas Beata,
Hellmann Andrzej,
Wierzbowska Agnieszka,
StellaHolowiecka Beata,
Zdziarska Barbara,
Calbecka Malgorzata
Publication year - 2011
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21996
Subject(s) - medicine , myeloid leukemia , complete remission , bone marrow , oncology , acute leukemia , multicenter study , myeloid , leukemia , cancer research , immunology , chemotherapy , randomized controlled trial
The aim of this study was to prospectively evaluate the impact of early bone marrow response on complete remission (CR) rate and long-term outcome in adults with acute myeloid leukemia. Bone marrow cytology was assessed on day 6 of induction treatment in 164 patients, revealing the presence of ≥5% blasts in 61 cases. In this subgroup the CR rate was significantly lower compared to the remaining patients (P < 0.00001) resulting in decrease of the overall survival (P = 0.002). Persistence of ≥5% blasts in bone marrow on day 6 of induction is an easily available surrogate marker to be used for treatment decisions.